Effective November 28, 2023, Aeglea BioTherapeutics, Inc. will change its Nasdaq Capital Market stock ticker symbol to SYRE from AGLE.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.8 USD | 0.00% | +2.36% | +75.65% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.65% | 1.52B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea BioTherapeutics, Inc. will Change its Ticker to SYRE from AGLE